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Abstract
Background
Tissue Angiotensin II (Ang-II), produced through local non ACE-dependent pathways, stim-
ulates liver fibrogenesis, renal vasoconstriction and sodium retention.
Aim
To highlight chymase-dependent pathway of Ang-II production in liver and kidney during cir-
rhosis development.
Methods
Liver histology, portal pressure, liver and kidney function, and hormonal status were investi-
gated in rat liver cirrhosis induced through 13 weeks of CCl4, with or without chymase inhibi-
tor SF2809E, administered between 4th and 13th CCl4 weeks; liver and kidney chymase
immunolocation and Ang-II content were assessed. Chymase immunohistochemistry was
also assessed in normal and cirrhotic human liver, and chymase mRNA transcripts were
measured in human HepG2 cells and activated hepatic stellate cells (HSC/MFs) in vitro.
Results
Rats receiving both CCl4 and SF2809E showed liver fibrotic septa focally linking portal
tracts but no cirrhosis, as compared to ascitic cirrhotic rats receiving CCl4. SF2809E
reduced portal pressure, plasma bilirubin, tissue content of Ang-II, plasma renin activity,
norepinephrine and vasopressin, and increased glomerular filtration rate, water clearance,
urinary sodium excretion. Chymase tissue content was increased and detected in α-SMA-
positive liver myofibroblasts and in kidney tubular cells of cirrhotic rats. In human cirrhosis,
chymase was located in hepatocytes of regenerative nodules. Human HepG2 cells
and HSC/MFs responded to TGF-β1 by up-regulating chymase mRNA transcription.
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Conclusions
Chymase, through synthesis of Ang-II and other mediators, plays a role in the derangement
of liver and kidney function in chronic liver diseases. In human cirrhosis, chymase is well-
represented and apt to become a future target of pharmacological treatment.
Introduction
In chronic liver diseases, liver fibrosis progression depends on interactions among injured
hepatocytes, inflammatory cells, and hepatic myofibroblast (MFs)-like cells that originate from
activation of hepatic stellate cells (HSCs) or portal fibroblasts. These interactions imply angio-
tensin II (Ang-II) production by activated HSCs [1], Ang-II binding to angiotensin type 1
(AT1) receptors in myofibroblasts, and promotion of transcription of genes of extracellular
matrix components, pro-fibrogenic cytokines, and collagenolysis inhibitors [2–4]. Therefore,
angiotensin-converting enzyme (ACE) inhibitors or AT1 receptor antagonists attenuate exper-
imental liver fibrosis [5, 6].
Endothelins promote liver fibrosis too. Three isoforms of endothelin bind to two receptors
(ETA and ETB) and both endothelins and its receptors are up-regulated in the fibrotic liver.
Stimulation of ETA receptors in HSCs promote an increase in intracellular-free calcium cou-
pled with cell contraction, proliferation and stimulation of fibrogenesis [7].
In the kidney, Ang-II and endothelins have several effects. Ang-II constricts the efferent glo-
merular arteriole, resulting in preservation of glomerular filtration, but peritubular capillary
hydrostatic pressure decreases and reabsorption of sodium and water in the tubular nephron
increases. In addition, Ang-II causes sodium reabsorption in the proximal convoluted tubule
through direct stimulation of AT1 receptors [8]. In patients with ascitic cirrhosis, renal plasma
flow (RPF) and glomerular filtration rate (GFR) inversely correlate with plasma levels of
endothelin-1 (ET-1) [9], and systemic infusion of ET-1 results in a prompt anti-natriuretic
response [10].
Interstitial concentrations of Ang-II in normal heart and kidney are approximately 100-fold
higher than in plasma [11], and most tissue Ang-II is synthesized locally and not taken up
from the circulation [12]. Moreover, increased synthesis of ET-1 has been described at least in
the cirrhotic liver [13].
Injection of ACE inhibitors into the renal artery shows that non-ACE-dependent pathways
account for 70% of Ang-II production in this interstitial compartment [14]. Moreover, in myo-
cardial extracts from humans and dogs, 90% of Ang-II-forming activity is accounted for by
chymase (a serine endopeptidase) and not by ACE (a peptidyl-dipeptidase) [15], and chronic
chymase inhibition attenuates the development of cardiac fibrosis and ventricular remodeling
after experimental myocardial infarction [16].
Chymase, in heart, renal tubules and ubiquitous mast cells, converts angiotensin I (Ang-I)
into Ang-II (so-called interstitial renin-angiotensin system [RAS]) [15], as well as ACE does it
in the systemic RAS. In areas of chronic inflammation, chymase converts also big endothelin
into ET-1 [17] and activates transforming growth factor beta (TGF-β) by stimulating its Ang-II
dependent synthesis [18].
Since both Ang-II and ET-1 stimulate liver fibrogenesis, promote sodium retention and
renal vasoconstriction, and are generated by chymase, we explore hepatic and renal content
and localization of chymase in the experimental rat model of cirrhosis with ascites due to
chronic carbon tetrachloride (CCl4) administration. Moreover, we investigate the role of
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chymase in progression of liver histological damage and hepatic and renal failure by taking
advantage of chronic administration of SF2809E, a selective oral chymase inhibitor. Finally,
chymase is searched for in tissue samples of normal and cirrhotic human liver and, in vitro, in
human activated HSC/MFs and hepatoblastoma cells.
Materials and Methods
Data collection in experimental ascitic liver cirrhosis (phase 1) is followed by immunohisto-
chemical and biomolecular tests performed in normal and cirrhotic human liver and, in vitro,
in cells derived from human cirrhotic liver (phase 2).
Phase 1: in vivo experimental study
Thirty male adult Wistar rats with advanced liver damage and twenty male adult Wistar con-
trol rats were studied. Advanced liver damage was induced by CCl4 (Riedel de Haen, Sigma-
Aldrich, Seelze, Germany) administered by gavage twice a week for 13 weeks [19]. Control rats
were studied following a similar period of standardized diet. On the study day, all procedures
were performed under general anesthetic (a mixture of intraperitoneal Ketavet 100 [Farmaceu-
tici Gellini, Sabaudia, Italy] and Rompum [Xylazine, Bayer A.G., Leverkusen, Germany]). Rats
were cared for in compliance with the European Council directives (No. 86/609/EEC) and with
the Principles of Laboratory Animal Care (NIH No. 85–23, revised 1985). Animals were pro-
vided with currently accepted veterinary care daily; no animal died prior to the experimental
endpoint despite the cirrhosis induction program; at the experimental endpoint rats were
euthanized by exsanguination through the aorta (read later). This scientific project was
approved by the Ethical Committee of the University of Torino (permit number: D.M. 94/
2011-B). Meiji Seika Pharma Co., Ltd., Yokohama, Japan, provided SF2809E, an oral chymase
inhibitor, after isolation from fermentation broth of the actinomycete strain SF2809, identified
as Dactylosporangium sp. [20]. Six compounds having chymase inhibitory activity were iso-
lated, with the highest inhibitory activity shown by compound VI, named SF2809E. It inhibits
chymase at the IC50 of 0.014–0.081μM, whereas it does not inhibit cathepsin G and chymotryp-
sin at the concentration of 20μM (specific chymase inhibition) [20].
Animal groups. SF2809E was dissolved in Tween 80 to obtain two different solutions in
the same volume of fluid (400 μl): F10 (10 mg/kg b.w.) or F20 (20 mg/kg b.w.). The animals
were divided into five groups of ten rats: controls (group G1), controls receiving F10 three
times a week for 9 weeks (G2), rats with ascitic cirrhosis caused by 13 weeks of CCl4 (G3), rats
receiving CCl4 for 13 weeks but receiving also F10 or F20 three times a week all through the 5
th
and into the 13th week of CCl4 (nine-week of SF2809E) (G4 and G5). 4 rats (group G0) were
sacrificed at the end of 4 weeks of CCl4 to assess the degree of liver histological damage that
preceded SF2809E administration.
Study protocol. G1-G5 rats, after respective weeks of treatment or observation, were anes-
thetized [19], laparotomy was performed, and the urinary bladder was emptied before clamp-
ing the urethral orifice for further urine collection. Shortly thereafter, infusion of inulin (IN)
10% (W/v) (Laevosan-Gesellschaft, Linz/Donau, Austria) and para-aminohippurate (PAH)
20% (W/v) (Nephrotest, BAG Gmbh, Munich, Germany) into the caudal vein was started to
assess glomerular filtration rate (GFR) and renal plasma flow (RPF) by steady-state plasma
clearances of IN and PAH (CIN and CPAH, respectively) [19, 21]. After the start of IN and
PAH infusion, a polypropylene catheter (0.7 mm diameter) was inserted into a small ileal vein,
gently advanced to the bifurcation of the superior mesenteric and the splenic veins, and portal
pressure was measured [22]. When IN and PAH steady-state plasma concentrations had been
reached [19], cardiac blood was sampled to assess plasma osmolality and concentrations of IN,
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PAH, sodium, potassium, bilirubin, albumin, aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), vasopressin (ADH), plasma renin activity (PRA), Ang-II, and norepi-
nephrine (N). Finally, urinary bladder was emptied to measure 90-min urine volume,
osmolality and sodium and potassium excretion rates. Rats were then euthanized by exsangui-
nation through the aorta. Five anesthetized rats in each group had their mean arterial pressure
evaluated through tail sphygmomanometry [22] prior to any surgical procedure. After sacrifice,
liver and kidneys of all rats were removed for further biomolecular studies. Rats belonging to
G0 had their livers just removed for assessment of matrix deposition through α smooth muscle
actin (αSMA) indirect immunofluorescence and Sirius Red staining.
Liver Sirius Red staining. Sirius Red staining was performed on formalin-fixed paraffin-
embedded liver sections (2 μm thick) with rapid exposure to Harry’s hematoxylin to stain
nuclei after staining in 0.1% Sirius Red F3B (Sigma—Aldrich, St. Louis, MO, USA). Computer
based morphometric quantification of liver fibrosis in groups G1-G5 was then performed [23].
Liver αSMA immunohistochemistry. Immunohistochemistry was performed on paraffin
liver sections (6 μm thick) with mouse monoclonal anti-αSMA (Sigma-Aldrich, Milan, Italy)
[24].
Liver Gomori trichrome staining. Gomori trichrome staining, with Engel-Cunningham
modifications, was performed [25].
Chymase protein concentrations in liver and kidney. For western blot analysis, blots
were incubated with goat polyclonal chymase antibodies (Santa Cruz Biotechnology, Inc.) and
antibodies against β-actin (Sigma, St. Louis, MO, USA) [24, 26]. The intensity of chymase
bands in each experiment was normalized to the intensity of the corresponding β-actin band,
used as internal standard of non-specific protein content.
Chymase indirect immunofluorescence in liver and kidney. Goat polyclonal anti-chy-
mase (Santa Cruz Biotechnology, Inc.) or mouse monoclonal anti-αSMA (Sigma-Aldrich,
Milan, Italy) primary antibodies were used [26]. Secondary antibodies were anti-goat C3y-con-
jugated antibodies (Amersham Biosciences, Braunschweig, Germany). In the kidney, anti-
αSMA antibodies were employed to highlight chymase in relation to the wall of renal arterioles.
DNA fluorescent dye DAPI was used to stain nuclei [27].
Liver and kidney chymase immunohistochemistry. Sections were incubated with rabbit
polyclonal antibodies against chymase (Bioss Inc., Woburn, MA, USA) and standard proce-
dures were applied [24].
Endothelin-1, Ang-II and TGF-β tissue concentrations (liver and kidney). ET-1 and
Ang-II levels in tissue homogenates were determined by RIA (Phoenix Pharmaceuticals, Inc.,
Karlsruhe, Germany) and through standard HPLC methods, respectively. Tissue levels of TGF-
β were determined through ELISA, (TGF-β Abcam Kit—code n° ab119558; Cambridge, MA,
USA).
Plasma and urine analyses. Plasma and urine concentrations of electrolytes, and IN and
PAH plasma concentrations were measured [19]. Plasma ADH, N and PRA were determined
as described elsewhere [28]. Plasma Ang-II levels were determined by enzyme immunoassay
(EIA) (RayBiotech Inc., Norcross, GA, U.S.A.). Plasma transaminases, albumin and total bili-
rubin levels were determined with automated Roche/Hitachi Cobas equipment.
Calculations. Sodium and potassium clearances (CNa and CK), filtration fraction (FF),
and fractional excretion of sodium (FENa) and potassium (FEK) were calculated [28]. CIN and
CPAH were calculated through the steady-state plasma clearance formula as:
Cx ¼ infusion rateðxÞ=ssP x
where ssP-x is the steady-state plasma concentration of x. CIN and CPAH were taken as
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measures of GFR and RPF, respectively [21]. Tubular free-water reabsorption (TF-WR) was
also calculated [29], through the formula:
TF WR ¼ Cosm V
where V is the urinary output (ml/min); Cosm is the osmolar clearance, which was computed
via the formula:
Cosm ¼ ðUosmxVÞ=Posm
where Uosm and Posm are urine and plasma osmolalities. Mean arterial pressure (MAP) was
calculated from the formula [22]:
1=3 ðsystolic blood pressure diastolic blood pressureÞ þ diastolic blood pressure:
Phase 2: data collection in human liver cirrhosis
Human liver chymase Immunohistochemistry. Immunohistochemistry was performed
on paraffin-embedded sections from: a) livers explanted prior to liver transplantation from
patients with hepatitis C virus (HCV)-related cirrhosis; b) surgical liver sections from patients
without cirrhosis but with hepatic metastases from colorectal carcinoma. Immunohistochemis-
try in these sections of "controls" was performed in areas placed 3 cm off the edge of metastases.
Human liver specimens were obtained after written informed consent from each patient. The
use of human material conforms to the ethical guidelines of the 1975 Declaration of Helsinki
and was approved for this study by the University of Torino Bioethical Committee. Sections
were incubated with polyclonal anti-chymase antibodies (Bioss BS-2353R). After blocking
endogenous peroxidase activity with 3% hydrogen peroxide and performing microwave anti-
gen retrieval, primary antibodies were labeled by using EnVision, HRP-labeled System
(DAKO) and visualized by 3’-diaminobenzidine substrate. For negative controls the primary
antibodies were replaced by isotype- and concentrations-matched irrelevant antibody.
Quantitative real-time RT-PCR. Chymase mRNA levels were measured in vitro by real-
time PCR in human HepG2 and HSC/MFs cells treated with TGF-β1 (10 ng/ml) up to 24
hours, using SoFast™ EvaGreen1 Supermix (Biorad) following manufacturer’s instructions.
Real-time PCR was performed using MiniOpticon Real Time PCR System. Oligonucleotide
sequence of primers used for RT-PCR were: sense 5’-GGGACTATCCACCTGCAAGA-3’;
reverse 5’- CCTCCTTGGCGTAGTAGTCG -3’. The relative mRNA expression level was
calculated by the threshold cycle (Ct) value of each PCR product and normalized with that of
Beta-Actin by using comparative 2-ΔΔCt method.
Statistical analysis. All comparisons were made by one-tailed Wilcoxon rank sum test for
paired or unpaired data, as needed. Results are expressed as means ± SD. Significance is
accepted at the 5% probability level.
Results
Influence of chymase on liver fibrogenesis and development of cirrhosis
13 weeks of CCl4 resulted in cirrhotic ascites in all animals belonging to group G3; rats treated
with both CCl4 and 20 mg/kg b.w. of the chymase inhibitor (G5) were devoid of ascites and
had smooth livers of normal weight (Table 1). In group G3 kidneys were hypertrophic but of
normal weight in G5 (Table 2). Gomori trichrome, Sirius Red (Fig 1) and αSMA immunohis-
tochemistry (Fig 2) showed liver cirrhosis with thick fibrotic septa in G3 rats, micronodular
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cirrhosis in rats receiving 10 mg/kg b.w. of the chymase inhibitor (G4), fibrosis with architec-
tural distortion in rats receiving both CCl4 and the larger dose of the chymase inhibitor (G5)
[30]. Batts-Ludwig classification of liver scarring [31] confirmed stage B scarring in G5, in
comparison with the stage D scarring (liver cirrhosis) displayed by G3 rats (Fig 3). Comparing
liver histological damage caused by 4 weeks of CCl4 in G0 vs. G5 rats, limited progression of
liver fibrosis occurred when SF2809E was used in high dosage (Fig 4). Morphometric com-
puter-based assessment of fibrosis showed 0.13 ± 0.037% fibrosis-index in the control group
(G1). A strong accumulation of collagen fibers was observed in rats treated with just CCl4 (G3)
(4.75 ± 0.35%, P<0.01 vs. G1). This was much less evident in G5 rats (2.1 ± 0.28% fibrosis
index, P< 0.03 vs. G3) [27].
Liver and kidney chymase content and immunostaining
In liver and kidneys of G3 rats there was a larger amount of chymase than in normal rats. In
the cirrhotic liver, chymase was found in activated αSMA-positive myofibroblast-like cells in
the fibrotic septa and at the periphery of regenerative nodules (Fig 5). In the kidney of G3 rats
chymase was located in the wall of the proximal and, to a larger extent, distal convoluted
tubules, but also in cortical arterioles, identified through αSMA-positive staining, and at the
vascular pole of the glomerulus (Figs 6 and 7).
Liver and kidney function (Tables 1 and 2)
Portal pressure and serum bilirubin are lower and plasma albumin higher in G5 than in G3
rats. Inhibition of chymase reduced hepatic and renal levels of angiotensin II, endothelin-1 and
TGF-β in G5 vs. G3 rats. Glomerular filtration rate, filtration fraction, urine flow rate, urinary
sodium and potassium excretion rates, and fractional sodium excretion were increased in G5
rats compared to cirrhotic rats in G3. Tubular free-water reabsorption, a direct measurement
of the tendence of the renal tubules to retain solute-free water, was reduced by chymase inhibi-
tion in G5 vs. G3 rats.
Table 1. Liver weight and function data, portal pressure, and hepatic tissue levels of Ang II and ET-1 in the different rat groups.
G1 (n = 10) G2 (n = 10) G3 (n = 10) G4 (n = 10) G5 (n = 10)
Liver weight (g) 10.1 ± 1.8 9.8 ± 1.5 8.9 ± 1.1d 9.4 ± 1.5 10.1 ± 1.6
Liver-to-body weight ratio (%) 2.4 ± 0.8 2.3 ± 0.9 2.6 ± 1.3 3.0 ± 1.9 3.0 ± 2.0
TGF-β (ng/mg liver prot.) 10.8 ± 2.1 11.2 ± 3.1 19.9 ± 2.7a 21.3 ± 4.1a 14.2 ± 3.2
Bilirubin (mg/dl) 0.2 ± 0.04 0.2 ± 0.03 2.8 ± 0.3a 1.7 ± 0.3 1.0 ± 0.2
Albumin (g/dl) 3.5 ± 1.1 3.7 ± 1.2 2.2 ± 0.9a 2.9 ± 0.9 3.0 ± 0.9
AST (UI/L) 51 ± 10 56 ± 16 143 ± 56b 106 ± 50b 174 ± 39b
ALT (UI/L 24 ± 7 22 ± 2 69 ± 27b 47 ± 22 66 ± 39b
Portal pressure (mmHg) 6.2 ± 1.1 5.3 ± 0.8 24.3±2.05a 19.0 ± 1 10.0±0.98
Ang II (pg/mg of total liver protein) 48 ± 10 52 ± 31 1400 ± 149b 1209 ± 122 260 ± 99y
ET-1 (pg/mg of total liver protein) 19.9 ± 3.7 16.6 ± 5.3 82.9 ± 16a 63.5 ± 17 63.7 ± 12
Data are means ± SD. G1: control rats; G2: controls receiving 10 mg/kg b.w. SF2809E; G3: cirrhotic rats; G4: rats receiving both CCl4 and 10 mg/kg b.w.
SF2809E; G5: rats receiving both CCl4 and 20 mg/kg b.w. SF2809E.
aP<0.01 versus G1 and G5.
bP<0.01 versus G1.
dP<0.03 versus every other group.
yP<0.03 versus G3. (Wilcoxon rank sum test).
TGF-β, transforming growth factor beta; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Ang-II, Angiotensin II; ET-1, endothelin-1.
doi:10.1371/journal.pone.0162644.t001
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Hormonal status and arterial pressure (Table 2)
G5 rats had normal levels of systemic plasma norepinephrine, vasopressin (ADH), Ang-II,
and PRA, showing preserved effective arterial blood volume. Ascitic cirrhotic rats (G3) had sig-
nificantly increased levels of these hormones in comparison with healthy controls. Arterial
blood pressure was not significantly different in the five rat groups, with a tendency towards
hypotension only in G3.
Human liver chymase immunohistochemistry and In vitro cell expression
(Figs 8 and 9)
Normal human liver shows lobular metabolic zonation for chymase at the periphery of lobules.
Conversely, hepatocytes of regenerative nodules contain a lot of chymase, especially near
fibrotic septa. Myofibroblast-like cells at the periphery of larger septa contain chymase too, but
to a lesser degree. Both human activated hepatic stellate cells and human hepatoblastoma cells
show basal expression of chymase mRNA and a significant increase in its expression after treat-
ment with TGF-β1.
Table 2. Kidney weight, arterial pressure, renal function, and systemic and renal hormonal levels in the different rat groups.
G1 (n = 10) G2 (n = 10) G3 (n = 10) G4 (n = 10) G5 (n = 10)
Kidney weight (g) 1.8 ± 0.08 1.8 ± 0.09 2.3 ± 0.09e 1.8 ± 0.06 2.0 ± 0.09
Kidneys-to-body weight ratio (%) 0.8 ± 0.1 0.8 ± 0.2 1.3 ± 0.2 e 1.0 ± 0.2 1.1 ± 0.4
MAP (mm Hg) 87 ± 9 88 ± 10 79 ± 15 83 ± 12 85 ± 12
TGF-β (ng/mg kidney prot.) 23.7 ± 5.4 20.1 ± 3.3 35.2 ± 5.3e 25.1 ± 4.1 22.1 ± 4
Ang II (pg/mg of total liver protein) 70 ± 21 78 ± 22 1150 ± 199c 999 ± 187 570 ± 91a
ET-1 (pg/mg of total liver protein) 2.02 ± 0.2 1.86 ± 0.1 1.99 ± 0.2 1.63 ± 0.2 1.45 ± 0.2a
Diuresis (ml/h) 1.0 ± 0.1 0.9 ± 0.1 0.8 ± 0.1d 0.6 ± 0.07 1.1 ± 0.1a
Natriuresis (μmol/h) 92 ± 7 89 ± 9 81 ± 6d 86 ± 7 105 ± 15a
FENa (%) 2.3 ± 0.2 2.1 ± 0.2 1.9 ± 0.1d 2.0 ± 0.2 3.1 ± 0.4a
Kaliuresis (μmol/h) 82 ± 16 78 ± 18 64 ± 34 47 ± 10 141 ± 15a
TF-WR (ml/h) 1.14 ± 0.3 1.12 ± 0.4 2.77 ± 0.7c 2.55 ± 0.8 1.67 ± 0.4a
GFR (ml/min/g of kidney tissue) 0.16 ± 0.03 0.16 ± 0.05 0.11 ± 0.02c 0.12 ± 0.02 0.13 ± 0.02b
FF (%) 45 ± 4 43 ± 4 41 ± 2d 38 ± 3 64 ± 5a
PRA (ng/ml/h) 20.4 ± 2.2 19.3 ± 2.0 22.2 ± 1.9c 21.7 ± 1.7 20.6 ± 1.1a
Plasma Ang-II (pg/ml) 246 ± 51 164 ± 68 358 ± 61c 320 ± 228 271 ± 42a
Plasma ADH (pg/ml) 240 ± 34 221 ± 39 359 ± 41c 350 ± 44 275 ± 39a
Plasma N (ng/ml) 202 ± 68 231 ± 71 249 ± 59c 252 ± 51 166 ± 51a
Data are means ± SD. G1: control rats; G2: controls receiving 10 mg/kg b.w. SF2809E; G3: cirrhotic rats; G4: rats receiving both CCl4 and 10 mg/kg b.w.
SF2809E; G5: rats receiving both CCl4 and 20 mg/kg b.w. SF2809E.
aP<0.01 versus G3.
bP<0.05 versus G3.
cP<0.01 versus G1.
dP<0.05 versus G1.
eP<0.03 versus every other group. (Wilcoxon rank sum test).
MAP, mean arterial pressure; TGF-β, transforming growth factor beta; Ang-II, Angiotensin II; ET-1, endothelin-1; FENa; fractional excretion of sodium;
TF-WR, tubular free-water reabsorption; GFR, glomerular filtration rate; FF, filtration fraction; PRA, plasma renin activity; N, norepinephrine; ADH,
vasopressin.
doi:10.1371/journal.pone.0162644.t002
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Fig 1. Morphological analysis of chronic liver disease progression. 13 weeks of CCl4 (G3): development of liver
cirrhosis (and ascites). The liver of rats receiving both CCl4 and the chymase inhibitor was characterized by a significant
prevention of fibrosis progression towards cirrhosis. This was maximal in animals treated with 20 mg/kg b.w. of the
chymase inhibitor (G5). Prevention of fibrosis progression is clearly documented by either Gomori trichrome staining or
Sirius Red.
doi:10.1371/journal.pone.0162644.g001
Fig 2. Morphological analysis of chronic liver disease progression through αSMA immunohistochemistry.
Administration of chymase inhibitor to healthy rats (G2) did not affect normal liver morphology. 13 weeks of CCl4 (G3):
development of liver cirrhosis (and ascites). The liver of rats receiving both CCl4 and the chymase inhibitor was
characterized by a significant prevention of fibrosis progression towards cirrhosis. This, already appreciable in G4, was
maximal in animals treated with 20 mg/kg b.w. of the chymase inhibitor (G5).
doi:10.1371/journal.pone.0162644.g002
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Discussion
Chymase inhibitor SF2809E, in this experimental setting, leads to prevention of histological
cirrhosis and liver decompensation despite 13 weeks of CCl4 administration, which instead
causes ascitic cirrhosis (Figs 1–4) with functional renal failure if chymase is not inhibited. Rats
receiving SF2809E 20 mg/kg (G5) show lower portal pressure and hepatic levels of Ang-II, ET-
1 and TGF-β, and improved liver function in comparison with the cirrhotic group receiving
only CCl4 (G3) (Table 1). Moreover, in G5 rats, effective arterial blood volume is preserved and
PRA, catecholamines, ADH and Ang-II levels are close to normal values (Table 2).
Fig 3. Batts-Ludwig diagram of progression of scarring in chronic liver diseases (reprinted with permission from
Am J Surg Pathol 1995; 19: 1409–1417). The beneficial effects of chymase inhibition limit fibrosis progression to stage B
scarring in G5, as compared to the stage D scarring (i.e. overt cirrhosis) detected in rats receiving CCl4 only (G3).
doi:10.1371/journal.pone.0162644.g003
Fig 4. Once the treatment with chymase inhibitor at higher dosage was started (after 4 weeks of CCl4), Sirius Red
staining confirms just a modest progression of liver fibrosis occurring in G5 group vs G3 group.
doi:10.1371/journal.pone.0162644.g004
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Fig 5. Panel A. Western blot of representative experiments showing chymase levels in tissue homogenate of
liver and kidney of control (G1) and cirrhotic (G3) rats. β-actin is internal standard to evaluate non-specific
protein expression in the homogenates. Panel B. Rat cirrhotic liver. Immunohistochemical location of
chymase in close proximity to fibrotic septa and at the periphery of regenerative nodules (magnification: 40x).
Panel C. Indirect immunofluorescence of hepatic distribution of chymase in rat cirrhotic liver. Chymase
location in activated αSMA-positive myofibroblast-like cells in the fibrotic septa and at the periphery of
regenerative nodules (magnification: 40x). Panel C includes: small images on the left side representing
image acquisition of single fluorescence identifying chymase (red fluorescence) and αSMA (green
fluorescence); a larger image (overlay, right side) offering electronic merging of fluorescent images plus
correspondent nuclear staining (blue DAPI staining).
doi:10.1371/journal.pone.0162644.g005
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Chronic chymase inhibition reduces Ang-II, ET-1 and TGF-β levels also in the kidney, with
ensuing improvement of GFR, filtration fraction, free-water clearance and natriuresis, in com-
parison with untreated cirrhotic rats (Table 2).
Key positions for Ang-II to influence liver matrix deposition and kidney function are those
of chymase-positive cells: at the periphery of regenerative nodules in the cirrhotic liver (Fig 5)
and in the wall of the renal proximal and distal tubules and in cortical arterioles (Figs 6 and 7).
Moreover, hepatocytes of normal human liver host chymase at the periphery of lobules, but
hepatocytes of regenerative nodules of cirrhosis contain an even larger amount of this enzyme
(Fig 8) Accordingly, in vitro human HepG2 cells and HSC/MFs do express chymase at baseline,
with further transcription of chymase’s gene after profibrogenic TGF-β1 (Fig 9). This shows
that in chronic liver diseases cytokines stimulate chymase overexpression, and chymase, in
turn, may activate further pro-TGF-β to its active and fibrogenic form, as reported in literature
[18]. Chymase up-regulation was reported also in human subjects with diabetic nephropathy
[32] and in the ischemic kidney of two-kidney/one-clip hypertensive hamsters [33].
Fig 6. Renal distribution of chymase. Panel A: Indirect immunofluorescence staining of kidney sections
from cirrhotic rats (G3 group). Panel B: Immunohistochemical staining for chymase in kidney sections from
either control animals (G1) or cirrhotic rats (G3). In the kidney of cirrhotic rats, chymase was found in the wall
of cortical arterioles (Panel A), in the wall of proximal convoluted tubules (Panel B, green arrows), in distal
convoluted tubules (Panel B, red arrows), and at the vascular pole of the glomerulus (Panel B, black arrow).
doi:10.1371/journal.pone.0162644.g006
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Up until now, in patients with chronic liver disease, a correlation between the number of
chymase-containing mast cells and liver fibrogenesis was reported [34], and a decrease in the
number of activated stellate cells was seen in chymase inhibitor-treated compared to placebo-
treated hamsters receiving CCl4 [35].
Pharmacologic inhibition or genetic ablation of components of the systemic RAS attenuate
experimental liver damage and fibrosis deposition by reducing the function of Ang-II [6, 36].
But ACE-inhibitors and AT1 receptor-antagonists aggravate the arterial hypotension and
hyper-reninism of ascitic cirrhosis [37, 38].
Since 80% of angiotensin II-forming activity in kidney, heart and blood vessels is dependent
on chymase [39], one might assume that chymase inhibitors, like ACE inhibitors, reduce arte-
rial blood pressure and increase plasma renin. On the contrary, blood pressure is not lowered
and renin not increased by chymase inhibitors in this and other studies [40]. This is due to
ACE being located in endothelial cells and chymase in mast cells of the vascular adventitia.
Moreover, systemic plasma contains effective serine protease (chymase) inhibitors [40].
Our group described, in experimental cirrhosis, the diuretic and portal hypotensive effects
of the acute inhibition of metallo-endopeptidase neprilysin [22, 27], which degrades the natri-
uretic peptide angiotensin-(1–7) into angiotensin-(1–4) [41], destroys atrial natriuretic factors
and generates endothelin-1 [27]. Now we are showing that hepatic αSMA-positive activated
stellate cells, actual cell protagonists of liver fibrogenesis, express both neprylisin [22] and chy-
mase, and therefore may both synthesize pro-fibrotic Ang-II and ET-1 and clear anti-fibrotic
angiotensin-(1–7) and natriuretic peptides.
Finally, in chronic liver diseases, the concurrent overexpression of chymase in liver and kid-
ney deserves further mention because production by this enzyme of fibrogenic vasoconstrictors
Fig 7. Renal chymase indirect immunofluorescence staining. Enhanced tubular expression of chymase
in cirrhotic rats. Goat polyclonal anti-chymase primary antibodies (Santa Cruz Biotechnology, Inc.) and anti-
goat C3y-conjugated secondary antibodies (Amersham Biosciences, Braunschweig, Germany) were used.
doi:10.1371/journal.pone.0162644.g007
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Fig 8. Chymase immunohistochemical localization in resected samples of normal and cirrhotic human liver.
Original magnification as indicated.
doi:10.1371/journal.pone.0162644.g008
Fig 9. Both human activated, myofibroblast-like, hepatic stellate cells and human hepatoblastoma cells show basal
expression of chymasemRNA and a considerable increase in its expression after stimulation with TGF-β1, earlier in
HepG2 cells and later in activated stellate cells.
doi:10.1371/journal.pone.0162644.g009
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and anti-natriuretic agents in both organs may well represent a further mechanism that makes
hepatic and renal disorders so tightly linked in the natural history of liver cirrhosis.
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